Business
Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results
Recruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites Details about CEDAR trial to be presented at 63rd
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"\nRecruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites\n\nDetails about CEDAR trial to be presented at 63rd ASH Annual Meeting and Exposition in December\n\n$395.0 million in cash, cash equivalents and restricted cash as of September 30, 2021\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nGraphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today reported recent business progress and third quarter 2021 financial results.\n\n“We continue to remain focused on execution as we work to carry out our vision to develop potential one-time cures for patients with a wide range of serious and life-threatening diseases, starting with sickle cell disease,” said Josh Lehrer, M.Phil., M.D., chief executive officer of Graphite Bio. “We were pleased to present preclinical data that are foundational to our sickle cell disease program at the Sickle Cell Disease Association of America’s National Convention last month, and we are excited to share details about our Phase 1/2 CEDAR trial of GPH101 during a poster presentation at the ASH Annual Meeting next month. Importantly, recruitment for our CEDAR trial is underway at multiple clinical trial sites, keeping us on track to enroll our first patient before the end of the year.”\n\nRecent Highlights and Upcoming Milestones\n\n\nActivated multiple clinical trial sites for Graphite Bio’s Phase 1/2 CEDAR trial of GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD). With patient recruitment and activation of additional clinical trial sites underway, the company remains on track to enroll the first patient in the trial before the end of the year and expects to report initial proof-of-concept data by the end of 2022.\n\n\nReceived acceptance of an abstract at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 11-14 virtually and in Atlanta. Graphite Bio will present details about the company's Phase 1/2 CEDAR trial of GPH101.\n\n\nPresented preclinical data for GPH101 at the 49th Annual SCDAA National Convention. The data presented support the ability of Graphite Bio’s gene editing platform...